Health Technology Assessment (HTA) support
Source partners with pharmaceutical, biotech, and health technology companies to develop robust, evidence–based HTA submissions for UK, Irish, and international reimbursement agencies.
We provide strategic guidance and hands-on support throughout the process, helping clients build clear, credible clinical and economic value stories that stand up to HTA assessor scrutiny.
Turning evidence into a case that survives committee scrutiny
The earlier the right expertise is involved, the more options remain open when it matters.
Our team has expertise in submissions to NICE, the SMC, the NCPE, and many others, with experience spanning early planning, evidence generation, submission development, and post-submission support.
How we can help
✔ HTA landscape assessments and early planning
✔ Early scientific advice and briefing materials
✔ HTA submission strategy and evidence planning
✔ HTA submissions to UK, European, and international reimbursement agencies
✔ HTA advisory boards, and clinical and HTA expert engagement
✔ Mock committee meetings and objection handling preparation
✔ All stages of HTA Post-submission support, including responding to assessor questions
Every HTA submission is different.
What persuades a committee is a value story that has already anticipated its objections. Many teams arrive with strong clinical and economic evidence but want a partner who has sat on the other side of the table, and knows exactly where an HTA committee will raise concerns, to help shape that evidence into a case built to withstand scrutiny.
Talk to us about your evidence, challenges, and timelines, and we’ll help you identify the strongest path to a positive recommendation.
Five stages of support across the HTA submission
We provide the technical depth and rigour that turns evidence into a submission built to withstand scrutiny.
1. Landscape assessment and early planning
We assess the reimbursement landscape for your technology and identify the evidence, timelines and agency requirements that will shape submission strategy, prior to pivotal data availability.
2. Evidence generation and scientific advice
We support early economic modelling and early scientific advice engagement and meetings, helping ensure the evidence being generated will hold up against agency scrutiny later.
3. Submission development
Literature reviews, economic modelling, statistical analysis, and medical writing come together into a submission-ready evidence package, built to the specific format and standard each HTA agency requires.
4. Submission and committee engagement
We manage the submission process end–to–end and prepare clients for committee engagement, including mock appraisals that stress-test the case in a supportive environment to practise, receive feedback, and build confidence before the committee meeting. We can also attend appraisal committee meetings on behalf of companies if required / requested.
5. Post-submission support
We support clarification/assessor question responses, resubmissions and ongoing engagement with the HTA agency.
Planning a HTA submission?
Getting the right support in place early, before the evidence is locked in, changes what’s possible later. Talk to our HTA team to discuss your next submission.
Why work with us?
✔ Our multidisciplinary team brings first-hand insight into HTA expectations, processes and decision-making.
Over 35% of our senior Source staff have previously worked with or at NICE, including experience across NICE committees, the Centre for Health Technology Evaluation, the Centre for Guidelines, the Decision Support Unit (DSU), External Assessment Groups (EAGs) and the Scientific Advice Programme.
✔ Our health economic modelling reflects how the technology performs in real clinical practice, and our medical writing turns that data into a value story an assessor can follow and trust.
We have supported over 65 HTA submissions in the UK and Ireland, achieving a recommendation rate of more than 95% in submissions with a final decision. This depth of experience and strategic expertise helps clients anticipate challenges, strengthen evidence packages and navigate the path to reimbursement with confidence.
Talk to our team about your evidence and timelines
Getting the economic model and the submission narrative right is what separates a case that holds up from one that unravels under questioning.
FAQ — Health technology assessment
What is health technology assessment (HTA)?
HTA is the formal process reimbursement agencies use to evaluate the clinical and economic value of a new medicine or health technology, informing decisions on funding and access. In the UK and Ireland, this includes bodies such as NICE, the SMC and the NCPE, each with its own submission requirements and evidence standards.
What does an HTA submission service actually include?
Full HTA support starts with strategic input, product positioning, advisory board engagement, and shaping the evidence story from the outset, so the technical work that follows is built to support it. That technical work covers literature reviews, clinical evidence synthesis, statistical analysis and health economic modelling, alongside the medical writing needed to turn that evidence into a submission, through to post-submission response.
Which HTA agencies do you support submissions to?
Source HE supports submissions to UK and Irish reimbursement agencies including NICE, the SMC and the NCPE, the European JCA, as well as international agencies.
How early should we involve an HTA specialist in a product's development?
Early scientific advice and HTA landscape assessment are most valuable well in advance of an HTA submission, often around Phase 2 or early Phase 3. At this stage evidence generation plans and trial design can still be shaped to meet an agency’s expectations.
What happens after an HTA submission is made?
HTA agencies typically raise clarification questions before a committee meeting, and Source supports this stage directly, including preparing responses and rehearsing committee scenarios through mock appraisals, so companies go into the meeting having already stress-tested their case.